news)

NEWS

Media Contacts:

Europe

Robert Sutherland
Mobile: +44  7917 551 666
Email: robert.sutherland@seqirus.com

United States

Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com

Asia Pacific

Melanie Kerin
Mobile: +61 (0) 417 436 329
Email: melanie.kerin@seqirus.com

Seqirus news releases

Seqirus news releases

First cell-based quadrivalent influenza vaccine approved for use in Europe
14 Jan 2019

This news release is intended for Health Professional media only.

Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
16 Nov 2018 News Release

The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.

New Data on Cell-Based Seasonal Influenza Vaccines
16 Nov 2018

This news release is intended for Health Professional media only.

Seqirus Cell-based Influenza Vaccine Nears European Approval
19 Oct 2018 News Release

Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season.

Seqirus Joining UIVI to Advance Universal Flu Vaccine Research
26 Jun 2018 News Release

Human Vaccines Project and Seqirus Partner to Advance Universal Flu Vaccine Research

New PNG Snakebite Project to Improve Access to Antivenoms
17 Apr 2018 News Release

The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management system.